Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveCompleted with results Location: USA

    Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled , protocol number Novartis CTBM100CUS03

    This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25 to 80%

    • Number of Visits:

      9

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: USA

    Phase 2 study of CTX-4430 in people with CF (EMPIRE) , protocol number Celtaxsys CTX-4430

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug CTX-4430 and will use a placebo control.

    • Age:

      18 Years to 30 Years

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      50% or greater

    • Number of Visits:

      15

    • Length of Participation:

      1 year

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    Persistent Methicillin Resistant Staphylococcus Aureus (MRSA) Growth in Respiratory Culture , protocol number DASENB10AO, PMEP11K1, JENNIN16K0

    This study will look at the safety and effectiveness of a 28-day course of vancomycin for inhalation in getting rid of the bacteria, Methicillan Resistant Staphylococcus Aureus (MRSA) from the respiratory tract of people with CF and persistent MRSA infection.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      7

    • Length of Participation:

      8 months

    Contact us about this clinical Trial >
  • Mucociliary ClearanceClosed to enrollment Location: USA

    Phase 3 study of inhaled mannitol in adults with cystic fibrosis , protocol number Pharmaxis DPM-CF-303

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug mannitol and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirements

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      6

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    STOP: Standardised Treatment of Pulmonary Exacerbations Pilot Study , protocol number FLUME13A1

    This study took place at multiple care centres across the US. The goal of the study was to better understand current treatment practices for pulmonary exacerbations and whether the CF Registry can be used for this type of study.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      4

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: USA

    IGNITE: Safety and effectiveness of gallium nitrate in adults with cystic fibrosis , protocol number GALLIUM-IP-13

    This study is taking place at multiple care centers across the US. It will look at the safety and effectiveness of IV gallium nitrate in adults with cystic fibrosis who are chronically infected with Pseudomonas aeruginosa.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      25% or greater

    • Number of Visits:

      5

    • Length of Participation:

      63 days

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    GOAL e2 Lung Clearance Index study in children who have a CFTR gating mutation , protocol number GOAL-OB-11 Cohort 4

    This study took place at multiple care centres across the US. It evaluated Lung Clearance Index (LCI) as an outcome measure for young children with CF.

    • Age:

      3 Years to 5 Years

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    GOAL-e2 Expansion Study , protocol number GOAL-OB-11 Expansion

    This is a prospective, multi-centre observational study. This study will look at samples from people with cystic fibrosis who have the R117H and other non-G551D gating CFTR mutations, many of whom are expected to be prescribed ivacaftor during the course of the study. This study is for ages 6 and above.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del of No Copies F506del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    PALS: Aztreonam Inhalation Solution (AZLI) Safety Study in Children with CF and Chronic Pseudomonas Aeruginosa , protocol number Gilead GS_US_205-0160

    This open-label study looked at the safety of Aztreonam Inhalation Solution (Cayston®) given three times daily for three 28-day on/28-day off cycles in children with cystic fibrosis and chronic Pseudomonas aueruginosa (PA) infection in the lower airways.

    • Age:

      Less than 12 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      6 months

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Phase 4 study to monitor the susceptibility of Pseudomonas aeruginosa to aztreonam in people with CF , protocol number Gilead GS-US-205-0128

    This 5-year study took place at multiple care centres across the US. It investigated the susceptibility of Pseudomonas aeruginosa isolates to the anti-infective drug aztreonam.

    • Age:

      1 Year and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 90%

    • Number of Visits:

      5

    • Length of Participation:

      5 years

    Contact us about this clinical Trial >
  • Displaying results 81-90 (of 130)
     |<  <  4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13  >  >|